-

09:50:20 AM

AGLE Stock News

AGLE - Aeglea BioTherapeutics Inc

03/17/23 5:30 PM

Nasdaq : AGLE

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the...

RHEA-AI

very positive

03/02/23 7:01 AM

Nasdaq : AGLE

earnings

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates. In 2023, we are highly focused on execution, specifically the...

RHEA-AI

positive

01/06/23 7:01 AM

Nasdaq : AGLE

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creationCortney Caudill, M.B.A., has been promoted to the newly created role of chief product officer to increase focus and efficiency in the advancement of clinical

RHEA-AI

neutral

12/02/22 4:05 PM

Nasdaq : AGLE

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the compensation committee of its board

RHEA-AI

very positive

11/30/22 7:01 AM

Nasdaq : AGLE

management

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jeffrey M. Goldberg as

RHEA-AI

positive

11/15/22 4:25 PM

Nasdaq : AGLE

management

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been

RHEA-AI

neutral

11/03/22 7:01 AM

Nasdaq : AGLE

earnings

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kgMAA for Pegzilarginase for the Treatment of Arginase 1 Deficiency Accepted for Review by the EMA$75.2 Million of Cash as of September 30, 2022; Runway into Fourth

RHEA-AI

neutral

10/19/22 4:05 PM

Nasdaq : AGLE

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today

RHEA-AI

neutral

10/04/22 7:01 AM

Nasdaq : AGLE

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing in the third cohort of the Phase

RHEA-AI

neutral

08/29/22 4:05 PM

Nasdaq : AGLE

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for

RHEA-AI

neutral

1 2 3 4 5 6 Next

AGLE Data

IndustryPharmaceutical Preparation Manufacturing
Websiteaegleabio.com
Security nameAeglea BioTherapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees101
Tags
- Health Technology
- Pharmaceuticals: Major
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.